Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 0.60 |
| ▸ | PIK3R1 | P27986 | 13/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.60 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.60 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11902066 | 1.00 | PIK3CD (0.60) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL11901736 | 0.89 | PIK3CD (0.67) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL11901733 | 0.89 | PIK3CD (0.67) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL11900537 | 0.89 | PIK3CD (0.67) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL11901999 | 0.89 | PIK3CD (0.49) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL11901996 | 0.89 | PIK3CD (0.49) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL356142 | 0.89 | PIK3CD (0.67) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| Ammonia Solution, Strong SCHEMBL11901513 | 0.85 | PIK3CD (0.49) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL11902147 | 0.85 | PIK3CD (0.51) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL11901928 | 0.83 | PIK3CD (0.66) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2673269-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-18 | — | — | EP | claimed |
| WO-2012107465-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | claimed |
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | PIK3CD 2/4885PIK3R1 20/4885PIK3CG 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.